

## 2017 Glaucoma Pharmaceuticals Report

A Global Market Analysis for 2016 to 2022



# What's New

**AUTHOR**  
Peter Downs

**RELEASED**  
August 2017

The outlook for the glaucoma pharmaceuticals market is growing more positive as new products with new mechanisms of action begin commercialization or enter the final stages of the regulatory approval process. Market Scope estimates the glaucoma pharmaceuticals market will reach \$5.3 billion in 2022. However, prospects vary considerably by region.

## Market Scope

# 2017 Glaucoma Pharmaceuticals Report

Market Scope's 2017 Glaucoma Pharmaceuticals Report provides in-depth coverage of commercialized and investigational glaucoma medications in the market.

### Four Disease Categories Are Analyzed In This Report:


Primary Open-angle Glaucoma (POAG), Primary Angle-closure Glaucoma (PACG), Other Secondary OAG and ACG, and Ocular Hypertension (OHT)

### Each Market Segment Includes:

An Analysis of Market Competitors and Five-Year Forecasts for Market Performance

### Also Included in This Report:

- Overview of Glaucoma
- Prevalence of Glaucoma and Diagnosed Cases
- Glaucoma Care Providers
- Diagnosing Glaucoma
- Treating Glaucoma
- Glaucoma Medications in the Marketplace
- Development Pipeline for Glaucoma Rx
- Adjunctive Drugs Used in Glaucoma Surgery
- 26 Company Profiles
- 54 Color Tables and 36 Color Figures



Our report on the glaucoma pharmaceuticals market, now in its fourth edition, is a leading industry source for accurate and relevant information on all aspects of the glaucoma pharmaceuticals market. The glaucoma pharmaceuticals market is one of the largest and most complex market segments in ophthalmology with a variety of drug classes, as well as proprietary and generic versions of many drugs. Current ocular hypotensive medication classes used to treat glaucoma were developed 20 years ago or more, and generic versions of these medications are now in widespread use.

> This report includes market data for 2016, and we forecast market performance through 2022.

## How to Order

Order your 2017 Glaucoma Pharmaceuticals Report now at [www.market-scope.com](http://www.market-scope.com) or contact us directly via email or phone.



### ENTERPRISE LICENSE

2017 Glaucoma  
Pharmaceuticals Report  
**\$9,750**

*(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)*



### SINGLE-USER LICENSE

2017 Glaucoma  
Pharmaceuticals Report  
**\$6,500**

+ Additional Printable Electronic PDF **\$500**  
+ Additional Paper Copy **\$300**



### ONE-YEAR SUBSCRIPTION

Ophthalmic Market  
Perspectives Newsletter  
**\$900**

*(Outside the US — \$950)*

314.835.0600 | [info@market-scope.com](mailto:info@market-scope.com)

*Please add \$50 for shipping if ordering from outside the US.*

## Our Process

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective ophthalmic experience and each data point is driven by a combination of sources, including the following:

- Our proprietary global disease population and demographic models
- Twenty years and counting of ophthalmologist survey data
- Analysis of company published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in major, worldwide ophthalmic meetings
- Interviews and long-standing relationships with company executives and practicing ophthalmologists



# About Us

Market Scope is recognized as the leading source for accurate and timely industry information in ophthalmology.

We have been conducting primary research and producing comprehensive reports on ophthalmic markets since 1996. Our data, analysis, and forecasts serve as starting points for many annual planning cycles, strategic plans, acquisition analyses, and return-on-investment decisions in the industry. In addition, our information is routinely included in annual reports, SEC filings, and investor presentations by leading ophthalmic companies.

## TABLE OF CONTENTS

### INTRODUCTION

Scope of Report  
Methodology  
About the Author  
The Report at a Glance

### EXECUTIVE SUMMARY

Glaucoma and its Prevalence  
The Global Market  
Current Market Competitors  
Factors Shaping the Marketplace

### ABOUT GLAUCOMA

Open-Angle Glaucoma (OAG)  
Normal-Tension Glaucoma as a Subset of OAG  
Exfoliation Glaucoma (XFG) as a Subset of OAG  
Angle-Closure Glaucoma (ACG)  
Risk Factors for Primary Glaucomas  
Secondary Glaucomas  
Pigmentary Glaucoma  
Neovascular Glaucoma  
Uveitic Glaucoma  
Trauma-Related Glaucoma  
Steroid-Induced Glaucoma  
Lens-Induced Glaucoma  
Iridocorneal Endothelial Syndrome  
Congenital Glaucoma  
Ocular Hypertension (OHT)  
Genetics of Glaucoma

### PREVALENCE OF GLAUCOMA

Overview of Glaucoma Prevalence Research  
Global Prevalence by Disease Type  
Factors Shaping Worldwide Distribution of Glaucoma  
Diagnosed POAG  
Diagnosed PACG  
United States  
Western Europe  
Japan  
Other Wealthy Nations  
China  
India  
Latin America  
Rest of World  
Growth in Glaucoma Populations

### GLAUCOMA CARE PROVIDERS

Overview of Providers, Diagnosis, Treatment  
Care Providers and Diagnostic Facilities  
US Providers  
US Ophthalmologists and Glaucoma Specialists  
Profile of the US Ophthalmologist  
Profile of the US Optometrist  
Western Europe's Providers  
Ophthalmology and Health Care Systems  
Optometry  
Japan's Providers  
Ophthalmology and the Health Care System  
Optometry  
Other Wealthy Nations' Providers  
Ophthalmology and Health Care Systems

Optometry  
China's Providers  
Ophthalmology and the Health Care System  
Optometry  
India's Providers  
Ophthalmology and the Health Care System  
Optometry  
Latin America's Providers  
Ophthalmology and Health Care Systems  
Optometry  
Select Country Snapshots  
Rest of World's Providers  
Ophthalmologist and Health Care Systems  
Optometry  
Glaucoma Organizations and Foundations

### DIAGNOSING GLAUCOMA

Tonometry  
Pachymetry  
Perimetry or Visual Field Testing  
Ophthalmoscopy  
Fundus Photography  
Optical Coherence Tomography  
Confocal Scanning Laser Ophthalmoscopy  
Scanning Laser Polarimetry  
Glaucoma Scope Examination  
Slit Lamp Biomicroscopy  
Gonioscopy with Contact Lens  
Ultrasound Biomicroscopy  
Diagnosed Disease Rates  
Growth in Glaucoma's Diagnosis

### TREATING GLAUCOMA

Treatment Modalities  
Rx Medications  
Treating Open-Angle Glaucoma  
Treating IOP in Ocular Hypertension Patients  
Treating Exfoliation/Pseudoexfoliation  
Glaucoma (XFG/PEG)  
Treating Angle-Closure Glaucoma  
Limitations of Current Medications  
Referral to Glaucoma Specialists  
Laser and Surgery  
Laser Procedures  
Traditional Surgical Treatment  
Newer Surgical Approaches  
Traditional Medicine and Alternative Therapies  
China  
India  
Other Alternative Medicine  
Marijuana

### THE CHALLENGES OF MANAGING GLAUCOMA

The Key Role of IOP  
A Competing Theory Regarding IOP and Glaucoma  
Growing Glaucoma Treatment Options  
How Ophthalmologists Determine the Best  
POAG Treatment Option  
POAG Stages and Typical Treatment Approaches

### GLAUCOMA MEDICATIONS IN THE MARKETPLACE

Rho Kinase Inhibitor  
Prostaglandin Analogs and Prostaglandin Synthase Inhibitors  
Beta Blockers  
Alpha Agonists  
Selective Alpha Adrenergic Agonists  
Nonselective Alpha Adrenergic Agonists  
Carbonic Anhydrase Inhibitors  
Cholinergic Agonists  
Fixed Combination Medications  
Comparative IOP Reduction: Brands and MOAs  
The Market Mix: Original Medications and Generics  
Branded Proprietary IOP-lowering Medications  
Generic IOP-lowering Medications  
Branded Generics

### FORECAST FOR THE GLAUCOMA PHARMA MARKET

Prospects in Wealthy Nations  
Economic Shifts in Emerging Markets  
Changing Role of Glaucoma Procedures  
Global Market for Glaucoma Medications  
The Global Market by Medication Class  
The Global Market by Competitor  
Forecast for the Global Glaucoma Rx Market  
US Market for Glaucoma Medications  
Western Europe's Market for Glaucoma Medications  
Japan's Market for Glaucoma Medications  
OWN's Market for Glaucoma Medications  
China's Market for Glaucoma Medications  
India's Market for Glaucoma Medications  
Latin America's Market for Glaucoma Medications  
ROW's Market for Glaucoma Medications

### DEVELOPMENT PIPELINE FOR GLAUCOMA PHARMA

Prostaglandin Analogs  
Bausch + Lomb/Nicox: Vyzulta  
Nicox: NCX 470  
Ono Pharmaceutical/Santen Sepetaprost  
Santen/Novagali Pharma: Catioprost  
Rho-kinase Inhibition  
Aerie Pharmaceuticals: Rhopressa  
pH Pharma PHP-201  
Discontinued Rho-Kinase Inhibitors  
Adenosine Receptor Agonists and Antagonists  
Inotek Pharmaceuticals: Trabodendoson  
Acorn Biomedical: ACN-1052  
Discontinued Adenosine Receptor Agonists  
EP Receptor Agonists  
Santen: DE-117 (omidenepeg isopropyl)  
Discontinued EP Receptor Agonists  
Additional IOP-lowering Compounds  
Sylentis: Bamosiran (SYL-040012)  
Neuroprotection and Neuroregeneration  
Quark Pharmaceuticals: QPI-1007  
Merz Pharmaceuticals: MRZ-99030

Other Neuroprotective Compounds  
Discontinued Candidates  
Fixed Combinations of Agents  
Aerie Pharmaceuticals: Roclatan  
Inotek: Trabodendoson Plus Latanoprost  
Laboratoires Théa: T2347  
New Drug Delivery Technologies  
Clinical Stage Programs  
Preclinical Programs  
Review of Investigational Technologies

### ADJUNCTIVE DRUGS USED IN GLAUCOMA SURGERY

Compounds Used Off Label  
Möbius Therapeutics' Mitosol  
Altacor/Esperante's ALT 401 (Tranilast)

### COMPANY PROFILES

Aerie Pharmaceuticals  
Akorn  
Allergan, PLC  
Amorphex Therapeutics LLC  
Bausch + Lomb  
Envisia Therapeutics  
Inotek Pharmaceuticals Corporation  
Laboratoires Théa  
Laboratorios Sophia, SA de CV  
Mati Therapeutics, Inc.  
Merz GmbH & Co. KGaA  
Möbius Therapeutics LLC  
Neurotech Pharmaceuticals, Inc.  
Nicox  
Novartis  
Ocular Therapeutix  
Ono Pharmaceutical Co., Ltd.  
Otsuka Pharmaceutical Co., Ltd.  
Pfizer  
pH Pharma  
Quark Pharmaceuticals  
Santen Pharmaceutical Co., Ltd.  
Sun Pharmaceutical Industries, Inc.  
Sylentis  
Teva  
ViSci Ltd.

*Market Scope*

9859 Big Bend Blvd, Suite 202  
St. Louis, MO 63122  
[market-scope.com](http://market-scope.com)